California State Teachers Retirement System reduced its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 9.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 55,329 shares of the biopharmaceutical company’s stock after selling 5,923 shares during the quarter. California State Teachers Retirement System’s holdings in SAGE Therapeutics were worth $3,447,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in SAGE Therapeutics by 5.9% in the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock worth $241,431,000 after acquiring an additional 168,424 shares in the last quarter. Vanguard Group Inc. increased its holdings in SAGE Therapeutics by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock worth $219,006,000 after acquiring an additional 58,679 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in SAGE Therapeutics by 36.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after acquiring an additional 724,494 shares in the last quarter. State Street Corp increased its holdings in SAGE Therapeutics by 7.7% in the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock worth $96,558,000 after acquiring an additional 87,097 shares in the last quarter. Finally, Oak Ridge Investments LLC increased its holdings in SAGE Therapeutics by 0.9% in the 3rd quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock worth $45,897,000 after acquiring an additional 6,835 shares in the last quarter. Hedge funds and other institutional investors own 95.33% of the company’s stock.

In other news, insider Albert Robichaud sold 60,000 shares of the company’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the sale, the insider now owns 152,759 shares of the company’s stock, valued at $24,354,367.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total transaction of $33,103,390.15. Following the sale, the chief executive officer now directly owns 211,473 shares of the company’s stock, valued at approximately $33,296,423.85. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Several brokerages recently commented on SAGE. Chardan Capital reissued a “hold” rating on shares of SAGE Therapeutics in a report on Wednesday, September 13th. Needham & Company LLC boosted their price target on shares of SAGE Therapeutics from $86.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, November 10th. BMO Capital Markets reissued an “outperform” rating and issued a $203.00 price target on shares of SAGE Therapeutics in a report on Thursday, December 7th. Canaccord Genuity set a $191.00 price target on shares of SAGE Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 7th. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $87.00 price target on shares of SAGE Therapeutics in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $171.21.

Shares of SAGE Therapeutics Inc (NASDAQ SAGE) opened at $162.61 on Tuesday. SAGE Therapeutics Inc has a 1-year low of $44.55 and a 1-year high of $173.36. The stock has a market cap of $6,680.00, a price-to-earnings ratio of -23.67 and a beta of 3.05.

SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. The company’s revenue for the quarter was up .0% compared to the same quarter last year. analysts predict that SAGE Therapeutics Inc will post -7.42 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “California State Teachers Retirement System Has $3.45 Million Position in SAGE Therapeutics Inc (SAGE)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/california-state-teachers-retirement-system-has-3-45-million-position-in-sage-therapeutics-inc-sage/1799446.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.